Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02947035 · ClinicalTrials.gov registry record · Phase 2
Molecular Testing to Direct Extent of Initial Thyroid Surgery
A Phase 2 study of Thyroid Cancer, sponsored by University of Pittsburgh.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 2
- Study locations
NCT02947035 is a Phase 2 study of Thyroid Cancer that has completed, run by University of Pittsburgh. The registered enrollment target is 100 participants, below the 280-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (64% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT02947035, a Phase 2 study of Thyroid Cancer, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 2
- Study locations
Study Summary
The research study consists of the participant agreeing to 1) the use of preoperative molecular testing (ThyroSeq) to guide extent of initial surgery and 2) the prospective collection of medical record data related to treatment of thyroid cancer.
Conditions Studied
Interventions
- PROCEDURE Thyroid lobectomy
- PROCEDURE Total thyroidectomy with CCND
Study Locations (2)
Pennsylvania
- University of Pittsburgh - Pittsburgh
Wisconsin
- Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2017-02-01 |
| Est. Completion | 2023-06-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02947035
The ClinicalTrials.gov registry entry for NCT02947035 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 280-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (64% lower). The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Thyroid Cancer appearing as the primary indexed condition, and to 2 interventions - of which Thyroid lobectomy is the first listed.
NCT02947035 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Pennsylvania, Wisconsin.
Frequently Asked Questions
What is clinical trial NCT02947035 about?
NCT02947035 is a clinical study titled "Molecular Testing to Direct Extent of Initial Thyroid Surgery". The research study consists of the participant agreeing to 1) the use of preoperative molecular testing (ThyroSeq) to guide extent of initial surgery and 2) the prospective collection of medical record data related to treatment of thyroid cancer.
What is the current status of trial NCT02947035?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2017-02-01. Estimated completion is 2023-06-01.
What conditions does trial NCT02947035 study?
This clinical trial studies the following conditions: Thyroid Cancer.
What interventions are being tested in trial NCT02947035?
The interventions under investigation include: Thyroid lobectomy (PROCEDURE), Total thyroidectomy with CCND (PROCEDURE).
Who is sponsoring clinical trial NCT02947035?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02947035 being conducted?
This trial has 2 study locations across Pennsylvania, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thyroid Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery
RECRUITING · Phase 2
-
The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer
RECRUITING · Phase 2
-
Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
RECRUITING · Phase 2
-
A Study of Avutometinib and Defactinib in People With Thyroid Cancer
RECRUITING · Phase 2
-
Comparison of I-124 PET/CT for the Diagnosis of Thyroid Cancer
RECRUITING · Phase 2
-
Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.